Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Actinogen Medical
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
July 20, 2026
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
June 1, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
May 23, 2026